KELIX bio was established in November 2020 and has since acquired manufacturing entities in India, Egypt, Malta, and Morocco, successfully commercializing a wide range of oral and injectable formulations spanning various therapy areas such as diabetes, oncology, cardiology, and central nervous systems.
This acquisition is poised to elevate the UAE's global stature in life sciences. With KELIX bio specializing in pertinent therapy areas and a seasoned leadership team proficient in effective buy-and-build strategies worldwide, this move aligns with Mubadala's objective to position the UAE prominently in the global life sciences sector.
Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala’s UAE Investments Platform, remarked, “In line with our responsibility as a prudent investor, this acquisition underscores Mubadala's ongoing contribution to accelerating the nation’s economic diversification through our portfolio companies and national champions.”
He further stated, “This collaboration marks a significant milestone in further advancing Mubadala’s foothold in the life sciences sector, with the aim of delivering enduring socio-economic benefits for our nation, including enhanced healthcare, pharmaceutical security, job creation, and GDP impact.”
Ismail Ali Abdulla, Head of UAE Clusters at Mubadala’s UAE Investments Platform, expressed, “At Mubadala, we are deeply committed to enhancing community well-being through strategic investments addressing critical healthcare needs. By bolstering our domestic capabilities in producing essential medications via KELIX bio, our objective is to significantly strengthen the UAE's healthcare infrastructure, ensuring broader access to life-saving treatments for all citizens. This investment underscores our dedication as a responsible investor, underscoring our commitment to investing in solutions addressing the world's most pressing challenges.”
Hocine Sidi-Said, co-founder and Chief Executive Officer at KELIX bio, commented, “We are immensely grateful to our previous shareholders for their confidence in our vision and for supporting a rapid acquisition program since inception. With Mubadala’s acquisition of KELIX bio, we embark on an exciting journey promising not only economic returns but also a lasting societal impact in the United Arab Emirates. We are eager to enhance the nation's manufacturing capabilities and drive an innovation agenda in diabetes, oncology, and biologics, among other areas.”
.png)
.png)
.png)
.png)
.png)
